Elevage is excited to announce that Suchira Sharma will be speaking at LSI USA ‘25 alongside a distinguished panel discussing the "Pros and Cons of Creative Financing Approaches for Growth in 2025." This engaging discussion will explore innovative funding strategies, risk balancing, and the future of Medtech investment. Panelists: - Barry Grossman — Partner, Ellenoff Grossman & Schole LLP - Luke Duster — Chief Investment Officer, CRG LP - Kyle Dempsey, MD, MBA — Partner, MVM Partners - Suchira Sharma — Principal, Elevage Medical Technologies - John White — Managing Director, KCK Medtech Join the conversation at LSI USA ‘25, taking place from March 17-21 in Dana Point, CA. #Medtech #Investment #LSIUSA25 #Elevage
Elevage Medical Technologies
Venture Capital and Private Equity Principals
Fueling Life-Changing Medical Technologies
About us
Elevage Medical Technologies is dedicated to supporting medical device companies that can meaningfully improve health outcomes and quality of life for patients. Through capital investment and strategic operational support, Elevage strives to accelerate the pace of innovation in the medical technology space. We provide capital and strategic support to growth-stage medtech companies to advance approval and commercialization. To learn more about Elevage, please visit www.elevagemedicaltechnologies.com
- Website
-
https://elevagemedicaltechnologies.com/
External link for Elevage Medical Technologies
- Industry
- Venture Capital and Private Equity Principals
- Company size
- 2-10 employees
- Type
- Privately Held
- Founded
- 2023
- Specialties
- medical devices, MedTech, Healthcare, Investing, and Finance
Employees at Elevage Medical Technologies
Updates
-
We are proud to announce that Suchira Sharma has been promoted to Principal at Elevage Medical Technologies! Since joining us as Vice President, Suchira has demonstrated exceptional leadership, strategic insight, and a passion for driving innovation in the medical technology space. Her ability to navigate complex challenges while fostering collaboration has been instrumental in the success of both our team and the companies we support. Suchira’s promotion reflects her dedication, expertise, and significant contributions to Elevage’s mission of accelerating impactful advancements in healthcare. We can’t wait to see all she will accomplish in her new role as Principal!
Thrilled to announce Suchira Sharma's promotion to Principal at Elevage Medical Technologies. Suchira has made a remarkable impact on Elevage's entire business, sourcing and executing new opportunities, and as a huge value-add to our partner companies. Congratulations, Suchira! Incredibly well deserved. Evan Melrose, MD, MBA and I could not be more proud. We're fortunate to have you as an integral part of this team. -- Josh Makower Peter Tortora Stacy Brown
-
Elevage is thrilled to announce our partnership with Fire1 and support their $120m financing to accelerate the mission of transforming the lives of millions living with heart failure.
🚀 Big news from FIRE1! 🚀 We’re thrilled to announce that FIRE1 has secured $120 million in financing to accelerate our mission of transforming heart failure care! This funding, led by Polaris Partners and Elevage Medical Technologies, alongside new investors Longitude Capital, Sands Capital and existing investors, will enable us to complete a pivotal clinical trial for our Norm™ heart failure management solution and brings us one step closer to completing our mission to give millions of people around the world with heart failure their normal back! Heart failure affects millions, yet traditional management remains reactive and hospital-centric. Norm™ empowers patients with physician-directed self-management, to reduce hospitalizations and ease the burden on healthcare systems. Breakthrough Device Designation We're also honored to receive Breakthrough Device Designation from the FDA and acceptance into the Total Product Lifecycle Advisory Program (TAP) based on our innovative approach in tackling one of healthcare’s greatest challenges. A warm welcome to Ellie McGuire (Polaris Partners) and Michael Wasserman (Elevage Medical Technologies) to our Board of Directors! This is more than just funding—it’s a step toward revolutionizing heart failure care and empowering patients worldwide. Stay tuned as we continue this exciting journey! 🔗 Learn more: www.fire1foundry.com Andera Partners New Enterprise Associates (NEA) Novo Holdings Lightstone Ventures Gilde Healthcare Gimv National Treasury Management Agency Seventure Partners Medtronic Maxwell Bikoff Jake Merrill #FIRE1 #HeartFailure #Patientempowerment #NormHF #YourNormalBack
-
We are pleased to announce that Nuclera has closed a $75 million Series C financing round led by Elevage Medical Technologies, a platform established by Patient Square Capital. The funding will be used to accelerate the commercialization of Nuclera’s eProtein Discovery system, which optimizes protein expression and purification workflows within research labs globally. Read more here: https://lnkd.in/evMmZrVD #DrugDiscovery #ProteinSynthesis #MedicalResearch #Healthcare #PrivateEquity
-
-
We are very excited Michael Wasserman will be joining the "Medtech's Conundrum: Where Will Capital and Liquidity Come From?" at #LSIEurope24. Thanks for the invitation, LSI - Life Science Intelligence. If you're attending, please reach out.
-
-
We are thrilled to share that Elevage Medical Technologies led this transformative round of funding. This milestone is a testament to Moximed’s dedication to pushing the boundaries in medical innovation and making a significant impact on patients’ lives. We look forward to the next steps in bringing the MISHA® Knee System to more patients around the world. Here’s to continued innovation and improving patient care! 🙌 #Moximed #ElevageMedicalTechnologies #KneeOsteoarthritis #MedicalInnovation #Healthcare #SeriesDFunding
#NEWS: We’ve secured #SeriesD financing for $91 million: https://lnkd.in/eYh3WgxQ Funds will be used to accelerate U.S. commercialization of the MISHA® Knee System. We’re grateful for the support from lead investor Elevage Medical Technologies, new investors Cormorant Asset Management, LP, Warren Point Capital, and existing investors New Enterprise Associates (NEA), Future Fund, Advent Life Sciences, Glide Healthcare, Vertex Ventures HC, GBS Venture Partners, and Morgenthaler. #Financing #MedTech #MoveToMISHA #KneeOA #Orthopedics #SportsMedicine
-